ArticleNucleic acids research2025
Nucleolar MED19 regulates 2'-O-methylation of rRNA in supporting cancer cell growth.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- MBD2 suppresses SFRP1 expression and promotes colorectal cancer development by blocking MED19 binding to its methylated promoter.Cancer biology & therapy · 2026Article
- The Mediator complex: co-transcriptional regulation and beyond.RNA biology · 2026Review
- Non-canonical subunit functions in multiprotein complexes: insights from the Mediator complex.Biochemical Society transactions · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The Mediator complex is a transcriptional co-factor for RNA polymerase II (Pol II)-dependent gene expression, with MED19 serving as an integral subunit. While MED19 overexpression has been documented in diverse cancer types to promote tumor progression, the underlying molecular mechanisms remain poorly understood. Here, we uncover a previously unrecognized function whereby MED19 localizes to the nucleolus independently of the Mediator complex. This nucleolar targeting is mediated by a conserved poly-lysine motif at the MED19 C-terminus, which enables binding to ribosomal RNA (rRNA) and fibrillarin (FBL), a catalytic component of the 2'-O-methyltransferase complex and pre-rRNA processing factor. Mechanistically, MED19 facilitates rRNA processing and 2'-O-methylation that promotes the efficiency of internal ribosome entry site-dependent translation for a number of onco-promoting genes including c-Myc. Collectively, these findings reveal a novel Mediator-independent function of MED19 in regulating ribosome-mediated translational control, thus providing mechanistic insights into its onco-promoting role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.